369 related articles for article (PubMed ID: 20055743)
21. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.
Perkhofer S; Jost D; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2008 May; 52(5):1873-5. PubMed ID: 18347112
[TBL] [Abstract][Full Text] [Related]
22. Multi-azole resistance in Aspergillus fumigatus.
Howard SJ; Webster I; Moore CB; Gardiner RE; Park S; Perlin DS; Denning DW
Int J Antimicrob Agents; 2006 Nov; 28(5):450-3. PubMed ID: 17034993
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
Guinea J; Peláez T; Alcalá L; Bouza E
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
[TBL] [Abstract][Full Text] [Related]
24. Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia.
Chryssanthou E; Loebig A; Sjölin J
J Antimicrob Chemother; 2008 Jun; 61(6):1309-11. PubMed ID: 18367461
[TBL] [Abstract][Full Text] [Related]
25. Human albumin promotes germination, hyphal growth and antifungal resistance by Aspergillus fumigatus.
Rodrigues AG; Araujo R; Pina-Vaz C
Med Mycol; 2005 Dec; 43(8):711-7. PubMed ID: 16422301
[TBL] [Abstract][Full Text] [Related]
26. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents.
Manavathu EK; Cutright J; Chandrasekar PH
J Clin Microbiol; 1999 Mar; 37(3):858-61. PubMed ID: 9986876
[TBL] [Abstract][Full Text] [Related]
28. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
29. In Vitro Interactions between Target of Rapamycin Kinase Inhibitor and Antifungal Agents against Aspergillus Species.
Gao L; Ding X; Liu Z; Wu Q; Zeng T; Sun Y
Antimicrob Agents Chemother; 2016 Jun; 60(6):3813-6. PubMed ID: 26976874
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp.
Yekutiel A; Shalit I; Shadkchan Y; Osherov N
Antimicrob Agents Chemother; 2004 Sep; 48(9):3279-83. PubMed ID: 15328085
[TBL] [Abstract][Full Text] [Related]
31. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
Manavathu EK; Abraham OC; Chandrasekar PH
Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
[TBL] [Abstract][Full Text] [Related]
32. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
Lewis RE; Wiederhold NP; Klepser ME
Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
[TBL] [Abstract][Full Text] [Related]
33. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
[TBL] [Abstract][Full Text] [Related]
34. In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex.
Badali H; Fakhim H; Zarei F; Nabili M; Vaezi A; Poorzad N; Dolatabadi S; Mirhendi H
Mycopathologia; 2016 Apr; 181(3-4):235-40. PubMed ID: 26615417
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
[TBL] [Abstract][Full Text] [Related]
36. Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-à-vis amphotericin B and itraconazole.
Ramani R; Gangwar M; Chaturvedi V
Antimicrob Agents Chemother; 2003 Nov; 47(11):3627-9. PubMed ID: 14576132
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
Morace G; Drago M; Scaltrito MM; Conti S; Fanti F; Polonelli L;
J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
Dannaoui E; Meletiadis J; Tortorano AM; Symoens F; Nolard N; Viviani MA; Piens MA; Lebeau B; Verweij PE; Grillot R; And The Ebga Network
J Med Microbiol; 2004 Feb; 53(Pt 2):129-134. PubMed ID: 14729934
[TBL] [Abstract][Full Text] [Related]
40. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
